Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
Go back to Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)| Merck & Co. (NYSE: MRK) | Delayed: 148.46 -1.87 (1.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.33 | 52 Week High | $65.46 | |||
| Open | $148.41 | 52 Week Low | $47.97 | |||
| Day High | $149.60 | P/E | 100.99 | |||
| Day Low | $146.28 | EPS | $1.47 | |||
| Volume | 11,187,248 | |||||
